HDII Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.08
Previous CloseN/A
Volume95.00K
Average Volume (3M)N/A
Market Cap
$285.00
Enterprise Value$13.68K
Total Cash (Recent Filing)$86.39K
Total Debt (Recent Filing)$651.32K
Price to Earnings (P/E)―
Beta-23.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding284,781,620
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-13.37
Price to Sales (P/S)0.00
P/FCF Ratio-1.83
Enterprise Value/Market Cap48.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HDII FAQ
What was Hypertension Diagnostics Inc’s price range in the past 12 months?
Hypertension Diagnostics Inc lowest stock price was <$0.01 and its highest was $0.08 in the past 12 months.
What is Hypertension Diagnostics Inc’s market cap?
Hypertension Diagnostics Inc’s market cap is $285.00.
When is Hypertension Diagnostics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hypertension Diagnostics Inc’s earnings last quarter?
Currently, no data Available
Is Hypertension Diagnostics Inc overvalued?
According to Wall Street analysts Hypertension Diagnostics Inc’s price is currently Overvalued.
Does Hypertension Diagnostics Inc pay dividends?
Hypertension Diagnostics Inc does not currently pay dividends.
What is Hypertension Diagnostics Inc’s EPS estimate?
Hypertension Diagnostics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypertension Diagnostics Inc have?
Hypertension Diagnostics Inc has 284,781,620 shares outstanding.
What happened to Hypertension Diagnostics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hypertension Diagnostics Inc?
Currently, no hedge funds are holding shares in HDII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hypertension Diagnostics Inc
Hypertension Diagnostics, Inc. (HDII) is a company that designs, develops, manufactures, and commercializes its own innovative, non-invasive medical technologies. These devices are engineered to identify minute changes in the flexibility of arteries, serving both domestic and international markets. Central to their offerings is the CVProfilor, a system designed for non-invasive assessment of both large and small artery elasticity. The elasticity of small arteries is especially critical, serving as the earliest and most sensitive indicator of cardiovascular disease. The product suite includes the CVProfilor DO-2020, which delivers essential arterial elasticity indices, aiding in the diagnosis of underlying vascular conditions. Its counterpart, the CVProfilor MD-3000, offers precise and specific insights into the presence of blood vessel disease. For scientific study, the HD/PulseWave CR-2000 is a specialized cardiovascular profiling system, equipping scientists and investigators with a non-intrusive method to evaluate arterial elasticity across diverse human research domains. These devices operate by capturing 30 seconds of blood pressure waveform data, subsequently analyzing the digitized patterns to generate a comprehensive CVProfile report. This report details crucial metrics including blood pressure, heart rate, pulse pressure, body surface area, body mass index, and indices for both C1 (large) and C2 (small) artery elasticity. HDII caters to a broad spectrum of clients, including general practitioners, cardiologists, various healthcare practitioners, skilled medical staff, academic and government research scientists, cardiovascular specialists, and pharmaceutical companies. In the U.S., sales are facilitated by a dedicated network of representatives. Established in 1988, Hypertension Diagnostics, Inc. maintains its headquarters in Richmond Hill, Canada.
Silexion Therapeutics
―
Bolt Projects Holdings
―
CERo Therapeutics Holdings
―
Syntec Optics Holdings
―
NewGenIvf Group
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors